Molecular mechanisms of lithium neuroprotection in Alzheimer's disease: A systematic comprehensive review.
Abstract
Alzheimer's disease (AD) contributes to most cases of dementia globally and is characterized by amyloid-β (Aβ) deposition, tau hyperphosphorylation, oxidative stress, and neuroinflammation. Existing treatments are merely management products that do not alter the course of the disease; thus, there is an urgent need to develop disease-modifying strategies for treating this condition. The multifaceted molecular effects of lithium have created new hope for neuroprotective interest in AD because of its wide utility in the treatment of mood disorders. Lithium also prevents the phosphorylation of glycogen synthase kinase-3β (GSK-3β), which in turn prevents tau pathology, mediates amyloid precursor protein (APP) processing, and regulates the interaction of β-catenin/Wnt to inhibit Aβ formation. Moreover, lithium helps maintain mitochondrial bioenergetics and calcium homeostasis, facilitates the autophagy of proteinaceous aggregates, and mediates microglial activity to reduce neuroinflammation. Preclinical and epidemiological evidence also indicates that lithium depletion may be an upstream regulator of AD pathophysiology, and that microdoses or modified formulations may help increase the safety and efficacy of lithium therapy. Although there is strong mechanistic and translational evidence, the clinical effects are inconsistent because of the narrow therapeutic window and lithium toxicity. Future directions include precision medicine, biomarker-guided treatment, and novel delivery systems that exploit the disease-mitigating effects of lithium in AD.